Worse Renal Outcomes in CKD Patients Linked to MetS
SAN DIEGO—Metabolic syndrome (MetS) in patients with stage 3 and 4 chronic kidney disease (CKD) is associated with an increased risk of development of end-stage renal disease (ESRD), according to a study presented at Kidney Week 2012.
The study by Sankar D. Navaneethan, MD, MPH, of Cleveland Clinic, and colleagues included 25,868 patients with stage 3 and 4 CKD. Of these, 15,605 (60%) had MetS. During a mean follow-up of 2.3 years, 3,345 participants died before reaching ESRD and 481 reached ESRD. Overall, MetS was associated with a 30% increased risk of ESRD while it was not associated with death among those with stage 3 and stage 4 kidney disease.
For the individual components of metabolic syndrome, elevated triglycerides, hypertension and impaired glucose metabolism were associated with a 7%, 67%, and 83% increased risk for ESRD, respectively, compared with the absence of these components.
“Our study findings reveal the higher prevalence of metabolic syndrome in patients with CKD,” Dr. Navaneethan told Renal & Urology News. “Metabolic syndrome is independently associated with end-stage renal disease. Whether interventions such as lifestyle modifications can improve the risk associated with metabolic syndrome on kidney disease progression merits further study.” Additional long-term studies examining the relationship between metabolic syndrome and death in this population are also warranted, he said.